Immunovant (IMVT)
(Delayed Data from NSDQ)
$27.17 USD
-0.58 (-2.09%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $27.13 -0.04 (-0.15%) 7:58 PM ET
2-Buy of 5 2
C Value D Growth A Momentum C VGM
Earnings News For IMVT
-
Why Is Immunovant, Inc. (IMVT) Down 14.7% Since Last Earnings Report?
-
Immunovant (IMVT) Up 3% as Q3 Earnings Top, Pipeline in Focus
-
Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended December 31, 2023
-
Immunovant (IMVT) Q2 Earnings Top Estimates, Pipeline in Focus
-
Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended September 30, 2023
-
Immunovant (IMVT) Q1 Loss Wider Y/Y, Pipeline in Focus
-
Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended June 30, 2023
-
Immunovant, Inc. (IMVT) Down 10.6% Since Last Earnings Report: Can It Rebound?
-
Immunovant (IMVT) Q4 Earnings Top Estimates, Pipeline in Focus
-
Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2023
-
Immunovant Reports Financial Results and Recent Business Updates for the Quarter Ended December 31, 2022
-
Immunovant's (IMVT) Q2 Earnings In Line, Batoclimab in Focus
-
Immunovant Reports Financial Results and Recent Business Updates for the Quarter Ended September 30, 2022
-
Immunovant (IMVT) Loss Narrows in Q1, Focus on Batoclimab
-
Why Is Immunovant, Inc. (IMVT) Up 13.9% Since Last Earnings Report?
-
Immunovant (IMVT) Sees Wider Q4 Loss, to Study Batoclimab in TED
-
Immunovant (IMVT) Reports Wider-Than-Expected Loss in Q3
-
Immunovant (IMVT) Reports Wider-Than-Expected Loss in Q2
-
Immunovant, Inc. (IMVT) Up 9.3% Since Last Earnings Report: Can It Continue?
-
Immunovant (IMVT) Reports Wider-Than-Expected Loss in Q1
-
Immunovant, Inc. (IMVT) Up 6.6% Since Last Earnings Report: Can It Continue?
-
Immunovant (IMVT) Reports Narrower-Than-Expected Loss in Q4
-
Immunovant, Inc. (IMVT) Down 12.1% Since Last Earnings Report: Can It Rebound?